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Endovascular repair of abdominal aortic aneurysm
(AAA) holds great promise in the advancement of
treating patients with this common disease. Mortality
and morbidity rates for endovascular repair compare
favorably with open repair in some series.1,2 Length of
stay (LOS) after endovascular AAA repair has been
reduced dramatically compared with open repair.1-3
Convalescence after endovascular repair has been sim-
ilarly shortened. Patient satisfaction and short-term
quality of life after endovascular AAA repair may be
improved when compared with open repair. If long-
term durability of these devices is favorable, this inno-
vative technology will significantly improve treatment
for many patients with infrarenal AAA.
Although the first endovascular devices used for
AAA repair were constructed from available conven-
tional grafts and stents,4 it became clear that an
entirely new hybrid technology would be optimal for
this minimally invasive treatment. The past decade
has seen an explosion of interest in this area by an
industry that has made a significant financial com-
mitment in development of these devices. With the
recent commercial introduction of endografts for
AAA repair from two manufacturers in the United
States, industry must decide appropriate pricing for
these devices. Ideally, the pricing will balance indus-
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Background: Technology-driven innovation in medicine is frequently associated with
higher costs than conventional therapy. A significantly higher cost for endovascular
($21,250, n = 190) versus open abdominal aortic aneurysm (AAA) repair ($12,342, n
= 60) was suggested by a direct cost analysis of patients in a multicenter trial. Estimated
inpatient costs (not charges) incurred nationwide by hospitals for endovascular and open
repair of AAA were studied to validate these observed trends. 
Methods: A retrospective analysis of 131 patients undergoing endovascular AAA repair
was compared with 49 patients undergoing open repair as part of a Food and Drug
Administration phase II prospective multicenter clinical investigation (AneuRx-
Medtronic). A model to estimate costs was constructed using important clinical descrip-
tors of these patients. These clinical characteristics where then matched with those from
22,460 patients undergoing AAA repair obtained from a large national database
(Medicare Provider Analysis and Review). Estimated hospital cost was then assigned to
each study patient according to the national average of the total hospital costs for the
respective matched patients in Medicare Provider Analysis and Review.
Results: Total inpatient hospital costs of endovascular repair were significantly higher than
that of open repair ($19,985 ± 7396 versus $12,546 ± 5944, respectively, P =.0001).
Endograft device cost ($10,400) accounted for 52% of the total cost of endovascular
repair. The 1999 mean blended Medicare reimbursement for AAA repair was $18,989.
Conclusion: In this early development stage, hospital cost for endovascular AAA repair
is significantly greater than open repair when device cost greatly exceeds $5000.
Although incremental reductions in cost of endovascular repair may be anticipated if use
of diagnostic studies, operating time, and length of stay decrease, device cost has the sin-
gle greatest impact on the expense of endovascular AAA repair. At current device pric-
ing, mean blended Medicare reimbursement does not cover the cost of endovascular
AAA repair. (J Vasc Surg 2000;31:237-44)
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try’s need to recover their investments, while likewise
allowing hospitals to also cover their costs.
Most AAA repairs are currently reimbursed to
hospitals with a fixed amount determined by the
appropriate Health Care Finance Administration
diagnostic-related group (DRG).5 Extra costs for
innovative technology such as endovascular stent-
graft devices cannot be “passed on” to third party
payers as they might have been in the past. In this
restrictive reimbursement structure,6 cost savings in
other elements of health care delivery must offset
higher device costs to make them economically
viable. Because these devices may improve patient
care and reduce disability as compared with open
AAA repair, public opinion may eventually force
payers to consider an increase in reimbursement.
BACKGROUND
To examine costs of endovascular and open AAA
repair, we initially examined direct cost data from the
following patient cohorts. One hundred ninety
patients underwent endovascular AAA repair with the
AneuRx device (Medtronic-AneuRx, Santa Rosa,
Calif) as part of the phase I and phase II protocols of
the Food and Drug Administration (FDA) at 12 sites
in the United States (appendix). Immediately before
beginning endograft implantations, each center per-
formed five open AAA repairs each to create a control
group of 60 conventional AAA repairs. These patients
undergoing open AAA repair had to be eligible for
endograft implantation, and indeed, their demo-
graphics were similar.1 All procedures were performed
from May 1996 to November 1997.
Itemized charge statements and universal billing
forms (UB-92) were collected from clinical sites for
each endovascular and open procedure by an eco-
nomic consultant from AneuRx-Medtronic. The
UB-92 forms are used by every hospital to provide a
breakdown of charge data from cost centers at each
institution. The consultant from the sponsoring
company entered these data into a spreadsheet and
determined each activity for the endovascular and
open surgical patients and provided the authors with
summary data. Itemized statements were also selec-
tively used with the UB-92 because revenue codes
can be broadly grouped for numerous activities.
The average hospital costs of each cost category
for open and endovascular repair are summarized in
Table I. Endovascular repair of AAA had significant-
ly higher mean total hospital cost than open repair
($21,250 versus $12,345). Mean charges for
endovascular repair were likewise higher than that of
open repair ($44,902 versus $31,300). 
Total diagnostic costs, including preprocedure
and postprocedure imaging, were higher in the
endovascular group when compared with the open
group ($2860 versus $1342). Operating room costs,
including anesthesia and medical/surgical supplies,
were not different between the groups ($4554 open
versus $4709 endovascular). Device costs, however,
were significantly more expensive in the endovascu-
lar group ($10,200) than in the open group ($653).
Room and board, the intensive care unit (ICU), and
recovery costs were 38% lower in the endovascular
group versus the open group ($2616 versus $4207).
In this patient cohort, days in the ICU and total
hospital LOS were significantly reduced in the
endovascular group.1 Pharmacy and blood bank
costs were also lower in the endovascular group
($865 versus $1588).
Regrettably, no statistical analysis of this infor-
mation could be performed because neither the
standard deviation nor the raw data were supplied by
the consultant from the sponsoring company. When
pressed for this information, the consultant respond-
ed that he had been “asked to stop working on . . .
the project” (personal communication, electronic
mail, Donald Freeman, March 19, 1999) after cor-
porate officials of the sponsoring parent company
had reviewed the data. This action had been taken
because of “concerns over the [endograft] pricing as
presented in the abstract,”(personal communication,
electronic mail, Donald Freeman, March 19, 1999),
which had been submitted to the 1999 Society for
Vascular Surgery/International Society for Cardio-
vascular Surgery annual meeting. We were then left
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Table I. Hospital costs (US dollars) for AAA
repair estimated by direct cost analysis
Open repair Endovascular
(n = 60) (n = 190)
Preprocedure diagnostic 644 1100
Postprocedure diagnostic 698 1760
Total diagnostic $1342 $2860
Room and board 1099 752
ICU 1210 639
Recovery 1898 1225
Total bed costs $4207 $2616
OR 2642 2577
Anesthesia 940 1038
Medical/surgical supplies 972 1094
Total OR costs $4554 $4709
Pharmacy/blood 1588 865
Device 653 10,200
Grand total $12,342 $21,250
ICU, Intensive care unit; OR, operating room.
with information that we believed was accurate but
could not independently verify.
A model for hospital costs was constructed accord-
ing to patient descriptors from this clinical series, with
approximate costs applied from national averages of
matched patients using Medicare Provider Analysis
and Review (MEDPAR) data to validate the accuracy
of the above background information. Only inpatient
costs of the hospital were assessed. Professional
expenses were not included or examined.
METHODS
The initial patient cohort studied were the first
150 endovascular patients in the FDA phase II
AneuRx clinical trial compared with 60 open control
patients. Phase I AneuRx graft patients were exclud-
ed because they represented “learning curve”
patients. Mortality (1.3% versus 7.5%), procedure
time, blood loss, and ICU time were all significant-
ly lower (P <.05) in phase II than in phase I.1 In
addition, patients with missing data required for the
modeling analysis were excluded. 
In collaboration with Kathy M. Beusterien,
MPH, of Covance Health Economic and Outcome
Services Inc, clinical and medical resource utilization
profiles were developed for study patients, and these
profiles were matched with those appearing in the
MEDPAR 1997 data file. Study patients were
matched with patients in MEDPAR who had a diag-
nosis-related group (DRG) of 110 (major cardiovas-
cular procedures with complications) or 111 (major
cardiovascular procedures without complications);
an International Classification of Disease-ninth revi-
sion (ICD-9) diagnosis code of 441.4 (AAA, no
rupture); and an ICD-9 procedure code of 38.44
(resection of abdominal aorta with replacement).
Study patients were matched with patients in this
MEDPAR group on the basis of the following crite-
ria: age (<65 years or ≥65 years), sex, discharge sta-
tus (alive/deceased), ICU days, and total LOS.
An estimated hospital cost was assigned to each
study patient according to the average of the total
hospital costs for the respective matched patients in
MEDPAR. The specific steps were as follows:
Step 1: Identify each unique patient profile appear-
ing among the study patients on the basis of
the matching criteria. For example, one profile
could be age older than 65 years, male, dis-
charged alive, 2 ICU days, and 4 days LOS.
Step 2: Match each patient profile with patients
in the MEDPAR 1997 data file. 
Step 3: Calculate the average of the ICU, med-
ical/surgical supply, and total hospital
charges reported for MEDPAR admissions
matching the patient profile.
Step 4: Convert ICU, medical/surgical supply,
and total hospital charges to costs using the
respective hospitals’ cost-to-charge ratios
reported in Medicare’s Prospective Payment
System Payment Impact Profile. 
Step 5: The approximate cost of a conventional
aortic graft ($653) was subtracted from the
medical/surgical supply costs, and $10,400
was added for the AneuRx device for estimat-
ing the total hospitalization costs for the
endovascular patients.
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Table II. Patient characteristics used for modeling cost analysis
Open Endovascular
Risk factors (n = 49) (n = 131) P value
Age
<65 11 (22%) 21 (16%) NS
≥65 38 (78%) 110 (84%) NS
Male 40 (82%) 118 (90%) NS
Tobacco 42 (86%) 114 (87%) NS
COPD 18 (37%) 28 (21%) .035
Hypertension 25 (51%) 94 (72%) .009
Prior coronary intervention 25 (51%) 68 (52%) NS
Prior myocardial infarction 14 (29%) 47 (36%) NS
Peripheral vascular disease 11 (22%) 28 (21%) NS
Diabetes mellitus 4 (8%) 12 (9%) NS
ESRD 2 (4%) 6 (5%) NS
ASA risk
I-II 5 (10%) 13 (10%) NS
III 32 (67%) 90 (69%) NS
IV 11 (23%) 28 (21%) NS
ASA, American Society of Anesthesiologists; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; NS, not sig-
nificant.
All analyses were conducted using SAS, version
6.12. Values were presented using ranges, means,
and standard deviations, as appropriate. Patient char-
acteristics were compared between treatment groups
using a χ2 test for categorical variables and the
Student t test for continuous variables. The Mann-
Whitney U test, a nonparametric alternative to the
Student t test, was used to compare cost estimates.
RESULTS
The economic analysis from the clinical model
included phase II patients who had complete data
for the initial hospitalization. Of the 150 AneuRx
graft and 60 open surgical patients, 19 (13%) and 11
(18%) patients, respectively, were missing data
required for the modeling analysis. These patients
were excluded from the analysis, resulting in a total
of 180 patients (131 AneuRx graft and 49 surgical
repair patients) who were included. 
Patient characteristics. Demographic and clin-
ical characteristics were comparable between patient
groups, with the exception of chronic obstructive
pulmonary disease (COPD) and hypertension. A
higher proportion of patients in the open surgical
repair group had COPD compared with the AneuRx
graft group (37% versus 21%, P = .035), and a high-
er proportion of patients in the AneuRx graft group
had hypertension compared with the open surgical
group (72% versus 51%, P = .009) (Table II). 
More than 75% of patients in the study popula-
tion were 65 years of age or older, and more than
80% were male. Most patients were smokers, and
approximately 50% had undergone a previous coro-
nary intervention procedure (Table II). 
The demographic and clinical characteristics of
the study population (n = 180) were compared with
those of the 30 patients who were excluded from the
modeling economic analysis because of missing data.
The findings showed that these characteristics were
comparable with the exception of American Society
of Anesthesiologists (ASA) grade. Fewer patients
who were included in the analysis had an ASA grade
of IV compared with patients excluded from the
analysis (22% versus 42%, P = .027). 
Table III presents the medical resource utiliza-
tion by treatment group. Duration of anesthesia and
surgery were comparable between treatment groups.
Blood loss, ICU stay, and hospital LOS were higher
in the open group versus the endovascular group.
Patients in the open surgical repair group stayed in
the ICU and in the hospital for 2.0 and 8.0 days,
respectively, and patients in the endovascular group
stayed in the ICU and hospital for 1.1 and 3.9 days,
respectively (P <.01).
Estimated hospital cost from MEDPAR. With
the use of the matching criteria, 63 unique patient
profiles were identified among study patients. In the
MEDPAR 1997 data set, 22,460 patients had been
assigned a DRG of 110 or 111, an ICD-9 diagnosis
code of 441.4, and an ICD-9 procedure code of
38.44. Matches were identified for 55 of the 63 pro-
files on matching the patient profiles with those for
the 22,460 MEDPAR patients. For the eight remain-
ing profiles, the number of ICU days was broadened
into a wider range (eg, from 1 ICU day to 0 to 1 ICU
days) until matches were identified (for two patient
profiles, LOS was broadened to identify matches). 
Hospitalization costs were lower in the open sur-
gical group after converting charges to costs and
accounting for the cost of the AneuRx graft. The
estimated mean total hospitalization costs for the
endovascular and open surgical repair groups were
$19,985 ± 7396 (13,540-92,950) and $12,546 ±
5944 (7271-36,258), respectively (P = .0001).
Intensive care unit costs were higher in the open sur-
gical group compared with the endovascular group
($1083 ± 1339 [20-9489] versus $611 ± 1599 
[0-17,187], respectively) (P = .0001).
DISCUSSION
Despite a significantly shortened LOS and
reduction in bed day costs (Table I), endovascular
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Table III. Procedure-related medical resource utilization in modeling cost analysis
Open Endovascular P value
Anesthesia time (hr) 4.6 ± 1.6 4.4 ± 1.5 .3377
Procedure time (hr) 3.3 ± 1.4 3.1 ± 1.3 .3189
Pts requiring transfusion 21 (43%) 17 (13%) .001
Blood loss (mL) 1710 ± 1431 662 ± 646 .0001
ICU days 2.0 ± 2.3 1.1 ± 2.0 .0093
Total LOS (d) 8.0 ± 5.8 3.9 ± 3.6 .0001
ICU, Intensive care unit; LOS, length of stay.
repair was significantly more costly than open repair.
The device cost ($10,400) accounted for 52% of the
total expense and was clearly the single largest cost
center. Our background information also suggested
an increased costs for diagnostics in the endovascu-
lar group ($1518 more than open), which also con-
tributed to the greater overall hospital cost. 
There was a high correlation between the back-
ground information and the data derived from the
cost model in this analysis. Hospital costs for open
repair in this study ($12,546) were within 2% of that
suggested by the background information ($12,342).
In a recent presentation of endovascular and open
repair costs in a smaller group (n = 16 each) from a
single center, Seiwert et al7 estimated open costs to be
$12,714. Using cost accounting with Transition
Systems Inc, Patel et al8 estimated hospital cost of
open repair, exclusive of professional fees, to be
$12,381. This close concordance of cost estimates
suggests that the data are representative.
Excluding device costs, estimated hospital costs
of endovascular repair in this study ($9585) were
13.2% less than suggested by the background infor-
mation ($11,050). This latter analysis included
phase I patients not included in the modeling esti-
mates, which may help explain the higher costs. 
Estimated ICU costs were also similar among
modeling data from this study when compared with
the initial background information. Open repair was
associated with an ICU cost of $1083 with the mod-
eling analysis and $1210 from the background infor-
mation. Endovascular repair had a reduction in ICU
cost to $639 and $611 as estimated by the back-
ground information and modeling methodology,
respectively. 
A summary of the emerging literature regarding
costs of endovascular AAA repair is presented in
Table IV. This literature largely supports our con-
tention that an endograft cost significantly greater
than $5000 results in a higher overall hospital cost
when compared with open repair. In an Austrian
study, Holzenbein et al9 compared costs of two
groups of 22 patients, each receiving either endovas-
cular or open repair. Length of stay was reduced in
the endovascular group, but mortality in the open
group was 13.6% with no mortality in the endovas-
cular group. With an endograft cost of $4723, they
concluded that endovascular repair was less expen-
sive than open ($23,381 versus $26,642, respective-
ly). Seiwert et al7 presented costs of 32 patients, half
undergoing either endovascular or open repair. With
an endograft cost of $5000, they found equivalent
cost of endovascular and open repair ($12,905 ver-
sus $12,714, respectively). Both of these studies
found that with an approximate endograft cost of
$5000, the hospital cost of endovascular repair was
comparable with standard open repair. In a study
from Ouriel et al,11 the implantable device was
$8248 greater in the endovascular group (n = 33)
than in the open group (n = 93), contributing to an
overall $5985 greater hospital cost in the endovas-
cular group. Our results are in agreement with those
of Ouriel, suggesting that economic parity between
endovascular and open repair is not possible with an
endograft cost approaching $10,000.
This study was limited to an analysis of inpatient
hospital costs only; expenses incurred after discharge
were not included or studied. Although open repair
requires little ancillary follow-up, close evaluation
for endoleak with computed tomography (CT) is
suggested for endovascular repair. At present, a min-
imum of three postoperative CT scans are per-
formed within the first year: within the first month,
then at 6 and 12 months after repair. Endoleaks that
do not spontaneously seal generally require expen-
sive interventional treatment. Thus, the follow-up
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Table IV. Comparative mean hospital costs for open and endovascular AAA repair
Total cost
N LOS
(open/endo) Open Endo Difference Endo device
Current study 49/131 8.0/3.9 $12,546 $19,985 +$7,439 $10,400
Oriel10 93/33 9.8/2.6 N/A N/A +$5,985 $8,898*
Patel8 N/A 10/3 $12,381 $16,189 +$3,808 $8,000
Seiwert7 16/16 6.6/2.6 $12,714 $12,905 +$191 $5,000
Holzenbein9 22/22 22.8/14.9 $26,642 $23,381 (–$3,261) $4,723
No professional fees are included.
*With estimation of $650 for conventional graft cost. 
Endo, Endovascular; LOS, length of stay; N/A, not applicable.
for endovascular AAA repair is certainly more expen-
sive than open repair, further widening the global
economic cost between them.
Hospital costs versus societal cost-effectiveness.
It is important to underscore that societal cost-effec-
tiveness may not parallel in-hospital costs. Using
Markov decision analysis modeling, Patel and col-
leagues8 found that endovascular AAA repair was
indeed cost-effective when compared with other
socially accepted (and reimbursed) medical treatments.
Interestingly, this cost-effectiveness was relatively
insensitive to changes in acute costs associated with
endovascular repair. If a significant reduction in mor-
bidity and mortality could not be achieved compared
with open repair, however, endovascular repair was not
cost-effective. 
Unfortunately, societal good does not influence
the financial solvency of hospitals. The recent rash of
hospital mergers, bankruptcies, and buyouts by for-
profit hospital chains attest to the dire financial
straits that many hospitals are facing. Evidence of
societal cost-effectiveness as described above may
represent a valid reason to petition the Health Care
Finance Administration for an increase in hospital
reimbursement for endovascular AAA repair.
However, in the current health care environment, it
may be unrealistic to expect such an upward adjust-
ment. In fact, because of the significantly decreased
LOS associated with endovascular AAA repair, there
could be ill-conceived pressure to actually reduce
hospital reimbursement for this procedure.
Implications of DRG reimbursement on
endovascular repair. Can our hospitals afford
endovascular AAA treatment? The payer mix of
patients undergoing AAA repair is critical in under-
standing the potential payment schema to hospitals
for this procedure. In the United States, most AAA
repairs (68%) are paid by Medicare, 28% are paid by
third party carriers, and the remainder (<5%) are
self-paid or paid by other government insurance
(medicaid, CHAMPUS).11 Because Medicare pays
for the most of these procedures, Medicare’s reim-
bursement policies clearly have the greatest impact.
Medicare’s prospective payment system uses ICD-9
diagnosis and procedure codes to reimburse hospi-
tals for inpatient care by assigning each discharge to
a specific DRG. Use of the ICD-9 diagnosis code for
AAA (441.4) and procedure code for AAA repair
(38.44) will place most cases in DRG 110 or DRG
111, major cardiovascular procedures with or with-
out complications or comorbidity, respectively.
Approximately 83% of patients undergoing open
AAA repair currently fall into DRG 110, 8% fall into
DRG 111, and the remainder fall into other DRGs
(eg, thoracoabdominal, respiratory failure).11
Mean 1999 Medicare allowed payments were
approximately $20,000 (range, $16,000-$28,000) for
DRG 110 and $10,800 (range, $8,700-$15,000) for
DRG 111. Of patients with these DRGs undergoing
AAA in 1997, 19,945 (88.9%) were coded with DRG
110, and 2515 (11.1%) were coded with DRG 111.11
The blended mean Medicare reimbursement for AAA
with these DRGs was approximately $18,989.
What qualifies a patient to be in the higher pay-
ing DRG 110? Medicare considers a comorbidity as
a preexisting condition that, because of its presence
with a specific diagnosis, causes an increase in LOS
by at least a day in 75% of cases. Examples may
include COPD, renal failure, or heart failure. A
complication, defined as a condition that arises dur-
ing the hospital stay and prolongs the LOS by at
least a day, occurs in 75% of cases.
At a blended mean 1999 Medicare reimburse-
ment of $18,989, the average hospital will incur an
actual net loss of $996 according to the endovascu-
lar AAA repair cost estimates from this study.
Endovascular AAA repair placed in DRG 110 (mean
reimbursement, $20,000) will, on average, cover the
cost at $19,985. It is important to underscore, how-
ever, that many hospitals receive less than the mean
and may not cover their costs. If a patient is placed
in DRG 111, the mean reimbursement of $10,800
will fall well below the costs incurred by all hospitals.
Because of a possible reduction in complications
with the use of endovascular AAA repair when com-
pared with open repair, a greater percentage of cases
may be coded into DRG 111. This percentage of
cases into the low-reimbursement DRG might
become even greater if the size threshold for repair-
ing AAA fell with the use of this minimally invasive
technique.
Nationally, hospitals are currently not covering
their costs on open AAA repair with DRG 111, but
because it represents less than 10% of AAA repair,
these losses have been offset by the profit from most
of the patients who fall into the higher paying DRG
110.11 If endovascular AAA repair has fewer compli-
cations and/or causes greater utilization in healthier
patients, a much greater percentage may be reim-
bursed under DRG 111. This scenario could make it
fiscally difficult for hospitals to afford this technology.
It is vital to underscore the implications of the
wide variation in Medicare reimbursement for AAA
repair. Driven in part by higher labor costs, hospitals
in many large urban metropolitan areas receive sig-
nificantly higher DRG payments than the mean.
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Because of higher labor and other operating costs,
they have a greater per-day savings for reducing LOS.
For these hospitals, endovascular AAA repair (coded
with DRG 110) may be economically cost-effective,
even at an endograft cost of $10,000. For those areas
with Medicare reimbursement significantly lower
than the mean, supporting endovascular AAA repair
will be correspondingly more difficult.
Limitations of study. Estimating the true costs
for delivery of medical care is an elusive process.
Although the tabulation of direct supply costs (such
as endograft device cost) is relatively straightfor-
ward, accurately estimating the real costs incurred
from nursing, overhead, and other indirect expenses
can be daunting. Although some hospitals use spe-
cific cost accounting systems (such as Transition
Systems Inc), there is no uniformity in cost account-
ing across the country. One consistent methodology
must be used to perform a multicenter study on
cost. Applying cost-to-charge ratios to generated
charges is a well-characterized method of estimating
costs that can be used nationally. The cost-to-charge
ratios were specific to each cost center at each hos-
pital; these data are available from the MEDPAR
national database. All indirect costs are included
when using this methodology. 
As a retrospective analysis of data, this work is sub-
ject to the limitations inherent in a nonprospective
study. The cost data represent a modeling analysis of
a clinical trial that was not in any way designed to
study or control cost. Because of the investigational
nature of endografts, extensive testing and imaging
was mandated per protocol (and the FDA). Because
some of these costly diagnostic procedures may not
be routinely required in practice, costs associated with
their use may fall in the future. Postprocedure CT
scanning as an inpatient was a part of the protocol for
these patients. Intravascular ultrasound interrogation
was mandated per protocol, but this costly technolo-
gy may not be routinely required.
Is it appropriate to compare the cost of a new
technology in its earliest stages with a mature, well-
defined procedure? Incremental reductions in the
cost of endovascular AAA repair may be realized as
further experience is gained with these devices.
Reductions in operating room time could result in
some savings. Although operating time was not sig-
nificantly different between open and endovascular
repair in this initial series, more recent experience has
seen a steady decline in time in the operating room
for endovascular repair. Our operative time at the
Ochsner Clinic has fallen from a median of 2.8 ± 0.2
hours (mean 3.0) in phase II patients (n = 28) to 2.2
± 0.2 hours (range, 1.2-6.9, mean 2.5) in phase III
patients (n = 22).12 Length of stay for patients with
endovascular AAA has likewise seen reductions to a
median of 2 ± 0.7 days (range, 1-17, mean, 2.7).12 
Despite these potential modest incremental sav-
ings, endovascular repair of AAA will be unlikely to
ever achieve economic parity with open repair at cur-
rent device pricing. The average hospital cost of
open AAA repair is approximately $12,500 (Table
IV). After the subtraction of the endograft cost from
this study ($10,400), it is doubtful that endovascu-
lar AAA repair could ever be performed for the
remaining $2100. We believe that it is reasonable to
compare these forms of AAA treatment at this devel-
opment stage because the endograft device cost itself
is the major determinant of overall cost differences. 
Although the modeling methodology using
MEDPAR data appeared to provide accurate esti-
mates of cost, there were some potential shortcom-
ings. There were five clinical descriptors used: age,
sex, discharge status (alive/deceased), ICU days,
and total LOS. The cost of complications was not
directly captured, except as a reflection of increased
LOS. In this clinical trial, postoperative morbidity
was less in the endovascular group because of fewer
medical complications; the incidence of surgical
complications were similar.1 Costs incurred because
of those complications, over and above that of
increasing LOS, would not be captured. Radiologic
procedures were likewise not separately captured.
Because the endovascular group had significantly
higher imaging costs, the MEDPAR matches would
likely underestimate costs in this group. In summa-
ry, there are deficiencies in the model itself that
could bias the cost estimates in either direction.
Could the exclusion of all phase I patients and
those with incomplete data bias the modeling cost
estimates “against” endovascular repair? As docu-
mented by Zarins et al,1 the excluded phase I
patients had worse clinical outcomes than those in
phase II, reflected in significantly higher mortality,
longer ICU stays, and greater operative time and
blood loss. These patient outcomes are generally
associated with higher costs. Because all phase I
patients were collected at only a few institutions,
most clinical sites had their initial experience with
the AneuRx device in phase II. The phase I sites had
access to the device earlier in the trial and thus con-
tributed a greater relative percentage of patients
enrolled. However, as stated by Zarins et al,1 “There
was no difference in outcome between the three
centers that contributed the largest number of
patients (40% of the total) and the remaining nine
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centers.” Again, clinical outcome usually parallels
cost. Of the patients in phase II excluded because of
incomplete data, patient characteristics were similar
with the exception of a higher number of ASA IV
patients. By definition, these patients have greater
comorbidity and a greater likelihood of costly com-
plications. In summary, the patients excluded from
this study likely biased the cost analysis “in favor” of
endovascular repair, not against it.
CONCLUSIONS
In this early developmental stage in endovascular
AAA repair, use of endografts is associated with sig-
nificantly higher hospital cost than traditional open
repair when device cost greatly exceeds $5000. In
the future, further reductions in LOS and operating
time and the use of diagnostic tests with endovascu-
lar repair may produce greater cost savings than is
reflected in the current data. Presently, the greatest
cost is that of the device, accounting for approxi-
mately half of the total hospital cost of endovascular
repair in this study. At current device pricing, blend-
ed mean Medicare reimbursement does not cover
the hospital cost of endovascular AAA repair. 
Thanks to Kathy M. Beusterien, MPH, a consultant
from Covance Health Economic and Outcomes Services,
Inc, for her assistance in creating the modeling methodol-
ogy used in this study.
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Appendix. Study sites.
Institution Location
Arizona Heart Institute Phoenix, Ariz
Cleveland Clinic Foundation Cleveland, Ohio
Harbor-UCLA and VAMC Torrance, Calif
Lexington Medical Center West Columbia, SC
Northwestern Univ Chicago, Ill
Ochsner Clinic New Orleans, La
Sanger Clinic Charlotte, NC
SIU School of Medicine Springfield, Ill
Stanford Univ Medical Stanford, Calif
St Vincent’s Hospital Indianapolis, Ind
Surgical Care Assoc Louisville, Ky
Washington Hospital Washington, DC
